Literature DB >> 26493548

Prospective case-control study of efficacy of bilateral selective neck dissection in primary surgical treatment of supraglottic laryngeal cancers with clinically negative cervical findings (N0).

V Djordjevic1,2, B Bukurov2, N Arsovic1,2, M Dimitrijevic1,2, S Jesic1,2, V Nesic1,2, Z Petrovic1,2.   

Abstract

OBJECTIVE: To evaluate the efficacy of bilateral selective neck dissection of levels II-IV in elective and therapeutic management of the neck as a part of primary surgical treatment of patients with supraglottic laryngeal cancer and clinically negative cervical findings (N0).
DESIGN: Institutional, observational, case-control study with historic control of patients who underwent primary supraglottic tumour surgery, and a prospective cohort of patient, who underwent, besides the operation of primary tumour, bilateral selective neck dissection (level II-IV).
SETTING: University, tertiary level hospital, national referral centre. PARTICIPANTS: The study included 193 patients with supraglottic cancer and without palpable or ultrasound positive cervical findings who were surgically treated from 1988 to 2005. Besides the operation of primary tumour, all patients in the study group underwent bilateral selective neck dissection (level II-IV). Patients in the control group (N = 51) underwent primary tumour operation only and were followed up regularly. In cases with postoperative regional recurrences, the radical neck dissection was performed. All patients with histopathological confirmation of occult metastases were administered radiotherapy treatment (60 Gy) in the postoperative period. MAIN OUTCOME MEASURES: Five-year overall survival rate.
RESULTS: Occult cervical metastases were found in 18% of patients. They were present in level II in 77.5%, in level III in 20% of cases and in one patient in level IV (2.5%); the extracapsular spread was observed in 20% of cases. Postoperative regional metastases were found in 4.15% of cases in the study group, and in 11.8% in the control group, which proved to be significantly higher. The five-year overall survival rate showed no significant difference between the study group and the control group.
CONCLUSION: The incidence of postoperative regional recurrences could be reduced by performing bilateral selective neck dissection simultaneously with primary tumour operation, but with no influence on the survival rate.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26493548     DOI: 10.1111/coa.12570

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  4 in total

1.  Guidelines for the Surgical Management of Laryngeal Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Soon-Hyun Ahn; Hyun Jun Hong; Soon Young Kwon; Kee Hwan Kwon; Jong-Lyel Roh; Junsun Ryu; Jun Hee Park; Seung-Kuk Baek; Guk Haeng Lee; Sei Young Lee; Jin Choon Lee; Man Ki Chung; Young Hoon Joo; Yong Bae Ji; Jeong Hun Hah; Minsu Kwon; Young Min Park; Chang Myeon Song; Sung-Chan Shin; Chang Hwan Ryu; Doh Young Lee; Young Chan Lee; Jae Won Chang; Ha Min Jeong; Jae-Keun Cho; Wonjae Cha; Byung Joon Chun; Ik Joon Choi; Hyo Geun Choi; Kang Dae Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-03       Impact factor: 3.372

2.  Assessment of Occult Nodal Micrometastases to the Clinically Negative Contralateral Neck in Locally Advanced Supraglottic Squamous Cell Carcinoma.

Authors:  Ahmad Mohamed Eltelety; Mohamed Aly Abou-Zeid; Mena Esmat Abdelmalek; Ahmed Amin Nassar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-08-17

3.  The prognostic value of tumor depth for cervical lymph node metastasis in hypopharyngeal and supraglottic carcinomas.

Authors:  Lu-Lu Ye; Jia Rao; Xing-Wen Fan; Fang-Fang Kong; Chao-Su Hu; Hong-Mei Ying
Journal:  Head Neck       Date:  2019-01-28       Impact factor: 3.147

4.  Rational surgical neck management in total laryngectomy for advanced stage laryngeal squamous cell carcinomas.

Authors:  Arne Böttcher; Christian S Betz; Stefan Bartels; Bjoern Schoennagel; Adrian Münscher; Lara Bußmann; Chia-Jung Busch; Steffen Knopke; Eric Bibiza; Nikolaus Möckelmann
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-18       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.